Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 15 May 2024
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (MA review of TA554) [ID6290]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 15 May 2024
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [ID6198]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 4 June 2024
Elranatamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID4026]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 5 June 2024
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 June 2024
Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 17 July 2024
Teclistamab for treating relapsed or refractory multiple myeloma after 3 treatments (Review of TA869) [ID6333]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 14 August 2024
Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia [ID4042]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 16 October 2024
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 16 October 2024
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 13 November 2024
Lisocabtagene maraleucel for treating relapsed or refractory diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B after first-line chemotherapy [ID3887]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 December 2024
Ibrutinib for untreated mantle cell lymphoma [ID1221]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma [ID1444]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID1251]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma ID6202Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease ID6405Status:In development | In consultationProgramme:Health technology evaluationConsultation end date: 23 May 2024Expected publication date: TBC